```html

Jerusalem Disease (Leprosy / Hansen’s Disease) – A Patient‑Friendly Medical Guide

Overview

Jerusalem disease is an older, colloquial name for leprosy, also called Hansen’s disease. It is a chronic infectious disease caused by the bacteria Mycobacterium leprae (or the closely related M. lepromatosis). The disease primarily attacks the skin, peripheral nerves, mucous membranes of the upper respiratory tract, and the eyes.

Leprosy is not limited to any one age, gender, or ethnicity, but it is most common in areas with limited access to health care and in populations that experience overcrowding or poor nutrition. According to the World Health Organization (WHO), there were about 127,000 new cases reported worldwide in 2022, a steep decline from the >5 million cases recorded in the 1980s, thanks to multi‑drug therapy (MDT) and public‑health campaigns.

Although the disease is called “Jerusalem disease” in some historical texts, it is largely recognized today as leprosy or Hansen’s disease. Early detection and treatment can prevent disability and transmission.

Symptoms

Leprosy presents a spectrum of clinical manifestations, ranging from a single skin patch to widespread nerve damage. Symptoms often develop slowly—over months to years—so early signs can be subtle.

Skin Manifestations

• Hypopigmented or reddish patches: Often lighter than surrounding skin, may be numb.
• Loss of sensation within the patch (reduced ability to feel temperature, pain, or light touch).
• Thickened, raised lesions (plaques) that may become nodular.
• Hair loss (alopecia) in the affected area.
• Dry, scaly skin or patches that may ulcerate if traumatized.

Neurological Signs

• Peripheral nerve thickening: Palpable nodules especially at the elbows, knees, wrists, and behind the ears.
• Loss of sensation in extremities – especially hands and feet – leading to repeated injuries.
• Muscle weakness that can cause claw‑hand deformities or foot drop.
• Tunel‑like pain or burning sensations (often called “Leprous neuritis”).

Eye Involvement

• Dryness, reduced blinking, or lagophthalmos (inability to close eyelids fully).
• Corneal ulcers or cataracts secondary to nerve damage.

Upper Respiratory Tract

• Nasopharyngeal congestion, chronic rhinitis, or epistaxis.
• Loss of sensation in the nasal mucosa, leading to crusting and ulceration.

Systemic Features (Less Common)

• Fever, malaise, or weight loss in the reactional states (type 1 or type 2 leprosy reactions).
• Enlarged lymph nodes.

Causes and Risk Factors

The disease is caused by infection with Mycobacterium leprae, an obligate intracellular bacterium that grows best at cooler temperatures (30‑33 °C), which explains its predilection for skin and peripheral nerves.

Transmission

• Prolonged, close, untreated contact with an infected person who has a high bacterial load (especially multibacillary leprosy).
• Respiratory droplets are the most likely route; the exact mechanism is still under study.
• Transmission via skin lesions is possible but less common.
• There is no strong evidence for transmission through casual contact, shaking hands, or sharing utensils.

Risk Factors

• Geographic exposure: Living in or traveling to endemic regions (India, Brazil, Indonesia, Nigeria, Philippines).
• Close household contact with an untreated case.
• Genetic susceptibility: Certain HLA types (e.g., HLA‑DR2, HLA‑DQ1) increase risk.
• Immunosuppression: HIV infection, long‑term steroid use, or other conditions that weaken cell‑mediated immunity.
• Poverty and overcrowding: Limited access to health care, malnutrition, and poor sanitation raise risk.

Diagnosis

Accurate diagnosis combines clinical assessment with laboratory confirmation. Early diagnosis is essential to prevent irreversible nerve damage.

Clinical Evaluation

• Detailed skin and neurological examination (assessment of sensation, muscle strength, and nerve thickening).
• Classification according to the WHO or Ridley‑Jopling system: Paucibacillary (PB) (≤5 skin lesions) vs. Multibacillary (MB) (>5 lesions or positive smear).

Laboratory Tests

• Skin smear microscopy (Ziehl‑Neelsen or Fite‑Faraco staining) to detect acid‑fast bacilli.
• Skin biopsy with histopathology—granulomas and presence of bacilli support diagnosis.
• Polymerase chain reaction (PCR) for M. leprae DNA—highly sensitive, especially in early disease.
• Serologic tests (e.g., anti‑PGL‑1 antibodies) are useful for monitoring treatment response in MB patients but are not diagnostic alone.

Additional Assessments

• Baseline nerve function testing (monofilament testing, Vibration perception using a tuning fork).
• Ophthalmologic exam to detect early eye involvement.
• Electro‑diagnostic studies when significant neuropathy is suspected.

Treatment Options

Since 1981, WHO‑recommended multi‑drug therapy (MDT) has been the cornerstone of treatment, achieving cure rates >95 %.

Standard MDT Regimens

• Dapsone 100 mg daily (or weight‑based)
• Rifampicin 600 mg once a month (supervised dose)
• For MB only: Clofazimine 300 mg monthly supervised, plus 50 mg daily self‑administered

Form	PB (≤5 lesions)	MB (>5 lesions)
Duration	6 months	12 months (extendable to 24 months for relapse)
Drugs

Management of Leprosy Reactions

• Type 1 (reversal) reaction: Corticosteroids (prednisone 0.5‑1 mg/kg) to reduce nerve inflammation.
• Type 2 (erythema nodosum leprosum) reaction: Thalidomide (if not contraindicated) or high‑dose steroids; clofazimine also has anti‑inflammatory properties.

Adjunctive Care

• Physiotherapy and occupational therapy to maintain muscle strength and joint mobility.
• Custom orthotics, protective footwear, and hand splints to prevent injuries.
• Eye‑care measures: lubricating drops, protective glasses, and regular ophthalmology follow‑up.
• Nutrition counseling—adequate protein, vitamins A, C, D and zinc support immune recovery.

Lifestyle & Supportive Measures

• Adherence to medication (directly observed therapy often used in endemic areas).
• Avoiding alcohol and smoking, which can worsen peripheral neuropathy.
• Routine skin and nerve checks—self‑examination once a week.
• Psychosocial support: counseling, support groups, and community education reduce stigma.

Living with Jerusalem disease (Leprosy, also known as Hansen's disease)

With proper treatment, most people lead normal, productive lives. Below are practical tips for daily management.

Self‑Care Routine

1. Medication adherence: Keep a pillbox; set alarms for daily doses; attend monthly supervised rifampicin visits.
2. Skin protection: Inspect feet and hands daily for cuts, blisters, or loss of sensation; use soft socks, well‑fitted shoes, and padded gloves.
3. Exercise: Gentle range‑of‑motion activities (e.g., wrist circles, ankle pumps) to preserve joint flexibility.
4. Eye hygiene: Apply lubricating eye drops 2–3 times daily; clean eyelids with warm water; report any redness or vision changes promptly.
5. Nutrition: Aim for a balanced diet rich in lean protein, whole grains, fruits, and vegetables; consider a daily multivitamin if diet is limited.

Social & Emotional Well‑Being

• Connect with local leprosy support groups (e.g., International Federation of Anti‑Leprosy Associations).
• Educate family members about transmission to reduce fear and isolation.
• Seek mental‑health counseling if you experience anxiety, depression, or stigma.

Work & Daily Activities

• If nerve loss causes gait instability, discuss workplace accommodations (e.g., ergonomic tools, modified duties).
• Inform your employer about your condition only if you need reasonable adjustments; legal protections exist in many countries.

Prevention

While complete eradication remains a challenge, several strategies dramatically lower individual risk.

• Early case detection and treatment – reduces bacterial load and interrupt transmission.
• Contact prophylaxis – a single dose of rifampicin (SDR) given to close contacts after ruling out active disease (WHO recommendation).
• Vaccination research – the BCG vaccine offers partial protection; ongoing trials are evaluating new subunit vaccines.
• Improved living conditions – reducing overcrowding, improving sanitation, and ensuring adequate nutrition.
• Education – community outreach programs that demystify leprosy and promote prompt medical evaluation of skin patches or numbness.

Complications

If leprosy is left untreated or reactions are not adequately managed, serious complications can arise.

• Peripheral neuropathy leading to chronic ulcers, secondary infections, and possible amputations.
• Deformities such as claw hand, foot drop, or facial nerve palsy.
• Eye complications including cataracts, corneal ulceration, and blindness.
• Secondary bacterial infections of skin lesions or ulcers—may progress to sepsis.
• Psychosocial impact – stigma, social isolation, depression, and reduced quality of life.
• Rarely, leprous leukoencephalitis (central nervous system involvement) has been described.

When to Seek Emergency Care

---

**References**

• World Health Organization. Global leprosy (Hansen’s disease) update, 2022. WHO; 2023.
• Mayo Clinic. Leprosy (Hansen disease). https://www.mayoclinic.org/diseases-conditions/leprosy
• Cleveland Clinic. Leprosy (Hansen Disease) Overview. https://my.clevelandclinic.org/health/diseases/15055-leprosy-hansen-disease
• National Institute of Allergy and Infectious Diseases (NIAID). Leprosy Treatment Guidelines. https://www.niaid.nih.gov/diseases-conditions/leprosy
• Centers for Disease Control and Prevention. Leprosy (Hansen Disease) Fact Sheet. https://www.cdc.gov/leprosy
• Walker SL, et al. Global epidemiology of leprosy. The Lancet Infectious Diseases. 2020;20(3):e98‑e109.

```